"The primary goal of this project is to establish a complete hospital-based liver cancer database, profiles for data feature extraction,develop different cancer, prediction models. A Medical AI program to predict the poster treatment (including operationradiofrequency ablation) recurrence of liver cancer will be established. The program system will assist doctors in the medical decision, identify high-risk patients,adjust clinical follow-up programs."

This is a method for identifying single nucleotide polymorphisms (GALNT14 genotypes) of a target nucleic acid for predicting whether a patient suffering from HCC will respond to combination chemotherapy. Accordingly, physicians can decide whether the HCC patients should receive chemotherapyTACE. This method could also predict prognosis in multiple gastrointestinal cancers.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.

Our previous studies suggested that increase Cisd2 levels may attenuate the pathogenesis of NAFLD/NASH. Accordingly, potent Cisd2 activators with the capacity to enhance Cisd2 levels were identified through the screening of skeletally diverse collections and structural optimization. So far BPRCD0001S0 is the most potent Cisd2 activator obtained, which has been studied extensively. Data obtained revealed that BPRCD0001S0 has no detectable toxicity in vivo, can activate Cisd2 in liver and ameliorate obese-related and fructose-induced NAFLD/NASH.